For a long time, scientists depended on luck to find new proteins. In 1840, for example, the Friedrich Ludwig Hünefeld, a ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The shot is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. Read more at straitstimes.com. Read more at straitstimes.com.

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects.

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The health secretary fired all the members of the Advisory Committee on Immunization Practices late on Monday.